Carlson, Alise K. http://orcid.org/0000-0002-5791-5813
Amin, Moein http://orcid.org/0000-0002-9587-0644
Cohen, Jeffrey A. http://orcid.org/0000-0001-9245-9772
Article History
Accepted: 14 February 2024
First Online: 14 March 2024
Declarations
:
: No funding was received for this article.
: Alise K. Carlson reports personal compensation for consulting for Sanofi, Novartis, Bristol-Myers Squibb, and Vigil Neuro. Moein Amin reports fellowship grants from Novartis (NGC44741) and Biogen (23046PFEL). Jeffrey A. Cohen reports personal compensation for consulting for Astoria, Bristol-Myers Squibb, Convelo, EMD Serono, FiND Therapeutics, INMune, and Sandoz; and serving as an Editor of <i>Multiple Sclerosis Journal.</i>
: Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: AKC, MA, and JAC contributed to the concept and design and revised the draft. AKC and MA performed the search strategy and contributed to acquisition of resources and drafting the manuscript. All authors participated in reviewing and approving the final manuscript, and agree to be accountable for the work.